Studies performed in Nlrp3 knockout mouse models or using NLRP3 inhibitors actually suggest that the activation of the inflammasome is important in NAFLD progression to NASH and fibrosis development [176]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.